Bradley M. Kerr
- Pharmacology top 1%
- Pharmacogenetics and Drug Metabolism 4
- Virology top 5%
- HIV Research and Treatment 4
- Nephrology top 5%
- Gout, Hyperuricemia, Uric Acid 8
- Hepatology top 5%
-
- Pharmacological Effects and Toxicity Studies 6
-
- HIV/AIDS drug development and treatment 7
- HIV/AIDS Research and Interventions 3
-
- Case Reports on Hematomas 5
-
- Epilepsy research and treatment 3
- Co-authors
- Deanna L. KroetzSusan M. KleinFrank J. GonzalezKenneth E. ThummelR H LévyRené H. LevyPoe‐Hirr HsyuStephanie Webber
- Cited by
- PharmacologyVirologyNephrology
- Journals
- Antimicrobial Agents and Chemotherapy (5 papers)Epilepsia (3 papers)Clinical Pharmacology & Therapeutics (2 papers)
- Partner nations
- United StatesJapanFinland
In The Last Decade
Bradley M. Kerr
24 papers receiving 1.3k citations
Peers
Comparison fields: 5 of 95
- Pharmacology 375
- Virology 145
- Nephrology 142
- Hepatology 153
- Pediatrics, Perinatology and Child Health 366
Countries citing papers authored by Bradley M. Kerr
This map shows the geographic impact of Bradley M. Kerr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bradley M. Kerr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bradley M. Kerr more than expected).
Fields of papers citing papers by Bradley M. Kerr
This network shows the impact of papers produced by Bradley M. Kerr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bradley M. Kerr. The network helps show where Bradley M. Kerr may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Bradley M. Kerr, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 5 | |
| 2 | 2018 | 10 | |
| 3 | 2017 | 19 | |
| 4 | 2016 | 24 | |
| 5 | 2016 | 3 | |
| 6 | 2014 | 81 | |
| 7 | 2007 | 31 | |
| 8 | 2005 | 12 | |
| 9 | 2005 | 195 | |
| 10 | 2004 | 10 | |
| 11 | 2002 | 32 | |
| 12 | 2001 | 1 | |
| 13 | 2000 | 30 | |
| 14 | Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. | 1998 | 91 |
| 15 | 1994 | 371 | |
| 16 | 1993 | 54 | |
| 17 | 1993 | 21 | |
| 18 | 1991 | 35 | |
| 19 | 1989 | 7 | |
| 20 | 1989 | 70 |
About Bradley M. Kerr
Bradley M. Kerr is a scholar working on Nephrology, Virology and Hepatology, having authored 24 papers that have together received 1.4k indexed citations. Recurring topics across this work include Gout, Hyperuricemia, Uric Acid (8 papers), HIV/AIDS drug development and treatment (7 papers), Pharmacological Effects and Toxicity Studies (6 papers), Case Reports on Hematomas (5 papers), HIV Research and Treatment (4 papers), Pharmacogenetics and Drug Metabolism (4 papers), HIV/AIDS Research and Interventions (3 papers) and Epilepsy research and treatment (3 papers). The work is most often cited by research in Pharmacology (375 citations), Virology (145 citations) and Nephrology (142 citations). Bradley M. Kerr has collaborated with scholars based in United States, Japan and Finland. Frequent co-authors include Deanna L. Kroetz, Susan M. Klein, Frank J. Gonzalez, Kenneth E. Thummel, R H Lévy, René H. Levy, Poe‐Hirr Hsyu, Stephanie Webber, Bhasker V. Shetty and Barry Quart. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, Epilepsia, Clinical Pharmacology & Therapeutics, Drug Design Development and Therapy and JAIDS Journal of Acquired Immune Deficiency Syndromes.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.